tRNA anticodon cleavage by target-activated CRISPR-Cas13a effector
Science Advances · 26.04.2024 · 10 (17)
DOI: 10.1126/sciadv.adl0164 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 26.04.2024. Verfasst von Ishita Jain und 14 weiteren Autor:innen. Beteiligte Einrichtung: Waksman Institute for Microbiology, Rutgers, The State University of New Jersey, Piscataway, NJ, USA. Hauptthemen laut MEDLINE: RNA, Transfer, CRISPR-Cas Systems, Anticodon, Escherichia coli. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS.
Abstract (Originalsprache)
Type VI CRISPR-Cas systems are among the few CRISPR varieties that target exclusively RNA. The CRISPR RNA–guided, sequence-specific binding of target RNAs, such as phage transcripts, activates the type VI effector, Cas13. Once activated, Cas13 causes collateral RNA cleavage, which induces bacterial cell dormancy, thus protecting the host population from the phage spread. We show here that the principal form of collateral RNA degradation elicited by Leptotrichia shahii Cas13a expressed in Escherichia coli cells is the cleavage of anticodons in a subset of transfer RNAs (tRNAs) with uridine-rich anticodons. This tRNA cleavage is accompanied by inhibition of protein synthesis, thus providing defense from the phages. In addition, Cas13a-mediated tRNA cleavage indirectly activates the RNases of bacterial toxin-antitoxin modules cleaving messenger RNA, which could provide a backup defense. The mechanism of Cas13a-induced antiphage defense resembles that of bacterial anticodon nucleases, which is compatible with the hypothesis that type VI effectors evolved from an abortive infection module encompassing an anticodon nuclease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Waksman Institute for Microbiology, Rutgers, The State University of New Jersey, Piscataway, NJ, USA.
- Center for Molecular and Cellular Biology, Skolkovo Institute of Science and Technology, Moscow, Russia.
- Peter the Great St. Petersburg Polytechnic University, Saint Petersburg, Russia.
- Saint Petersburg State University, Saint Petersburg, Russia.
- Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Moscow, Russia.
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.
ORCID-Profile: Ishita Jain, Matvey Kolesnik, Konstantin Kuznedelov, Natalia Morozova, Anna Shiriaeva, Alexei Livenskyi, Laura Kazieva, Kira S Makarova, Eugene V Koonin, Sergei Borukhov, Konstantin Severinov, Ekaterina Semenova
Förderung
- NIGMS NIH HHS
Zitieren
APA
Jain, I., Kolesnik, M., Kuznedelov, K., Minakhin, L., Morozova, N., Shiriaeva, A., Kirillov, A., Medvedeva, S., Livenskyi, A., Kazieva, L., Makarova, K. S., Koonin, E. V., Borukhov, S., Severinov, K., & Semenova, E. (2024). tRNA anticodon cleavage by target-activated CRISPR-Cas13a effector. Science Advances, 10(17). https://doi.org/10.1126/sciadv.adl0164
Vancouver
Jain I, Kolesnik M, Kuznedelov K, Minakhin L, Morozova N, Shiriaeva A, et al. tRNA anticodon cleavage by target-activated CRISPR-Cas13a effector. Science Advances. 2024;10(17). doi:10.1126/sciadv.adl0164
BibTeX
@article{Jain2024,
author = {Jain, Ishita and Kolesnik, Matvey and Kuznedelov, Konstantin and Minakhin, Leonid and Morozova, Natalia and Shiriaeva, Anna and Kirillov, Alexandr and Medvedeva, Sofia and Livenskyi, Alexei and Kazieva, Laura and Makarova, Kira S and Koonin, Eugene V and Borukhov, Sergei and Severinov, Konstantin and Semenova, Ekaterina},
title = {tRNA anticodon cleavage by target-activated CRISPR-Cas13a effector},
journal = {Science Advances},
year = {2024},
volume = {10},
number = {17},
doi = {10.1126/sciadv.adl0164}
}
EUVIMED